Regeneron Pharmaceuticals Inc. and Sanofi said Monday said it has initiated a phase 2/3 trial to evaluate Kevzara in patients with severe COVID-19.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,